No abstract

The resistance to antibiotics in clinically important bacteria is one of the major global health concerns. Phage therapy could be one reliable alternative therapeutic strategy to combat these superbugs. In this study, we assessed host range of a novel bacteriophage, JHP, and characterized for its potential use in phage therapy. The bacteriophage demonstrated infectivity over a broad range of genera including multidrug resistant clinical isolates of Pseudomonas aeruginosa, members of family Enterobacteracae, and other important human pathogens. The antibacterial activity was highest at pH 7, and at temperature of 37 °C. The phage lytic activity gradually decreased till 60 °C and showed no activity when temperature was further raised. The bacteriophage could safely be stored at 4 °C or -20 °C. The latent period of the bacteriophage was 25 min and showed a burst size of 433 virions per cell. The size of JHP genome was approximately 30 kb. Family, Siphoviridae was assigned to JHP based on its icosahedral head with non-contractile tail. The diameter of JHP head and tail length was found 115 and 152 nm, respectively. To sum up, the broad spectrum Siphoviridae phage JHP is an ingenious candidate for phage therapy.

Volatile oil composition of leaves and fruits of Terminalia arjuna (Roxb.) was reported for the first time. Oils were extracted by microwave assisted hydrodistillation where yield of both oils were found to be 0.20% and their GC-MS analyses led to the identification of 65 and 48 constituents, respectively. Major constituents of leaves were carvacrol (11.17%), thymol (6.52%), α-terpinyl acetate (5.92%) and anethole (5.13%) while that of fruits were (E)-jsoeugenol (11.48%), furfural (8.25%), p-vinylguaiacol (6.8%) and p-ethylguaiacol (5.72%) that demonstrated a significant difference between composition of its aerial parts, however, 33 constituents were identical that showed similarity characteristics in quality of these oils. Both leaf and fruit oils were found active against pathogenic and drug-resistant microbes:

The discovery of direct-acting antivirals (DAAs) has revolutionized the treatment of hepatitis C worldwide. In contrast, pegylated interferon-alpha (PEG IFN-α), the older regimen, had limited success. However, the effect of DAAs on the expression of immunomodulatory genes involved in liver pathologies remains ambiguous. The objective of this study was to explore and contrast the effects of DAAs and PEG IFN-α on the expression of selected immunomodulatory genes. Fifty individuals were enrolled in the study and they were divided into five categories; healthy individuals, treatment-naive, DAAs-responders, DAAs-nonresponders, and interferon-relapsers. The effect of the therapies on the expression of transforming growth factor-beta (TGF-β), tumor necrosis factor-alpha (TNF-α), suppressor of cytokine signaling 3 (SOCS-3), copper/zinc superoxide dismutase (Cu/Zn SOD), interleukin 10 (IL-10), and collagen type 1 was analyzed. Expression analysis of the selected genes was done through real time polymerase chain reaction. A significantly increased expression of TGF-β was observed in the patients who received DAAs or PEG IFN-α, which suggests that patients receiving anti-HCV therapies are prone to developing fibrosis. Moreover, DAAs-nonresponders had higher expression of TNF-α, SOCS-3, and IL-10. The elevated expression of TNF-α and SOCS-3 insinuates that DAAs-nonresponders may develop insulin resistance and steatosis in the future.Finally, in addition to TGF-β, high expression of collagen was found in interferon relapsers, which suggests that these patients are the most susceptible to developing cirrhosis.

Measles causes more deaths than any other vaccine preventable disease. In 2016, the ruthless contagion claimed nearly 90,000 lives. In fact, the neglected disease is rebounding in many parts of the world. Several countries reported devastating outbreaks of measles in the past decade: Philippines, Romania, Germany, Italy, Bulgaria, and Vietnam, to name but a few. The story is no different in Pakistan. Pakistan has experienced multiple outbreaks of measles in the last six years. It has been nearly four decades since the establishment of the Expanded Programme on Immunisation (EPI) in Pakistan. Moreover, the country is also a part of the Measles and Rubella Global Strategic Plan (2012-2020), erected by the WHO. Despite that, the coverage against measles and other vaccine preventable diseases is direly poor in Pakistan. According to the Pakistan Demographic Health Surveys and the Pakistan Social and Living Standard Measurement, the current EPI coverage is 65% and 88% percent, respectively [1]. Each year, 2 million Pakistani children do not receive the first dose of measles vaccine [2,3]. The coverage of the second dose is further low: 53% [4].